Abstract: The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.

Abstract: Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.

Abstract: The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.

Abstract: The present invention relates to the treatment of psoriasis and other skin disorders. More particularly, the present invention relates to compositions for treating such disorders, the compositions comprising submicron size droplets of corticosteroids and salts or esters thereof with oily excipients. The present invention also relates to process for the preparation of such compositions.

Abstract: The present invention provides a stable, organoleptically acceptable topical formulation(s) of the tetracycline antibiotics or pharmaceutically acceptable salts or hydrates thereof for the treatment of acne.

Abstract: The present invention relates to pharmaceutical package comprising a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof, and a desiccant. Also, relates to a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof and a pH modifier, wherein pH modifier provides a pH range of about 5.5 to about 6.5 when dissolved or suspended in water at a concentration of 1% at 25° C. The invention also relates to processes for the preparation of such pharmaceutical preparation and use thereof for prophylaxis or treatment of circulatory diseases.

Abstract: The present invention relates to pharmaceutical compositions of mesalamine suppositories. In particular, the invention relates to pharmaceutical suppositories comprising mesalamine or salts thereof and at least two oily or fatty bases. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of ulcerative colitis or ulcerative proctitis.

Abstract: Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.

Abstract: The present invention relates to topical pharmaceutical compositions comprising fusidic acid and a corticosteroid. More particularly, the present invention relates to topical pharmaceutical compositions comprising fusidic acid and mometasone or halobetasol or their esters, processes for preparing the same, and the use of such compositions for prevention and treatment of dermal infections.

Abstract: A stable pharmaceutical composition in a semisolid dosage form comprising a therapeutic effective amount of solubilized calcipotriene in an anhydrous form is disclosed.

Abstract: The present invention discloses a novel azelaic acid topical pharmaceutical gel composition that does not contain lecithin and a process for its preparation.

Abstract: The present invention provides a composition, comprising fluocinonide in a vehicle comprising one or two penetration enhancers, solvents and emulsifiers wherein penetration enhancers are present in ratio of less than 0.90 to the total of the penetration enhancers, solvents and emulsifiers.

Abstract: The present invention generally relates to a pharmaceutical composition. More particularly, the present invention relates to a stable topical lotion comprising at least a therapeutically effective amount of an androstane steroid compound or a pharmaceutically acceptable salt or ester thereof and one or more occlusive agents.

Abstract: The present invention generally relates to a a topical composition, such as a dermatological cream, containing the corticosteroid compound hydrocortisone butyrate.

Abstract: Pharmaceutical topical oil in water type emulsion gels comprising ciclopirox or a pharmaceutically acceptable salt thereof are disclosed.

Abstract: A sustained release, mucoadhesive vaginal pharmaceutical composition is provided comprising (a) an effective amount of at least one active pharmaceutical ingredient and (b) a hydrophilic matrix having mucoadhesive properties and capable of providing a sustained release of the active pharmaceutical ingredient, the hydrophilic matrix comprising a hydrophilic polymer having a weight average molecular weight of at least about 100,000. Also provided are solid oral dosage forms comprising the sustained release, mucoadhesive vaginal pharmaceutical compositions.

Abstract: Pharmaceutical composition comprising a therapeutically effective amount of micronized particles of cilostazol or pharmaceutically acceptable salts or esters thereof, wherein at least about 50% of the micronized cilostazol particles have an effective average particle size of less than about 10 microns is provided.

Abstract: A pharmaceutical ointment composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredients comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) an ointment base; and (c) an effective amount of one or more skin penetration enhancers capable of percutaneous delivery of the macrolide related immunosuppressant through the skin. Also provided is a process for its preparation and methods for delivering a macrolide related immunosuppressant or a pharmaceutically acceptable salt or ester thereof through the skin of a mammal in order to treat conditions situated on and beneath the skin.

Abstract: Disclosed is an extended release pharmaceutical formulation containing at least an alpha-2 adrenergic agonist, such as tizanidine, for the treatment and prevention of spasticity in a subject, e.g., painful inflammatory conditions associated with skeletal muscle spasms.

Abstract: The present invention relates to pharmaceutical dosage forms which include an antifungal having poor solubility. The pharmaceutical dosage forms of the present invention further comprise non-spherical granules, which do not contain a coated core region and may be formed into pharmaceutically acceptable dosage forms. The antifungal active pharmaceutical ingredients include itraconazole, saperconazole, ketoconazole, voriconazole and fluconazole.